CPHI (CPHI)

CPHI (CPHI) Healthcare & Pipeline Overview

China Pharma Holdings, Inc. (CPHI) focuses on developing, manufacturing, and marketing generic and branded pharmaceuticals in China. Operating in the Drug Manufacturers - Specialty & Generic industry, CPHI faces headwinds with a small market cap and negative gross margin, requiring improved operational efficiency to capitalize on market demand.

What Is the Investment Thesis for CPHI?

The investment thesis for China Pharma Holdings, Inc. centers on its potential to capitalize on the growing demand for generic pharmaceuticals in China. With a small market capitalization, CPHI's ability to improve its operational efficiency and expand its product portfolio is crucial. Key value drivers include increasing market penetration and reducing its negative gross margin. Growth catalysts involve expanding into new therapeutic areas and leveraging its existing distribution network. However, investors must consider the company's current financial struggles, including a negative profit margin of -76.9% and a highly competitive landscape. The company's success hinges on its ability to execute its turnaround strategy and achieve profitability.

Based on FMP financials and quantitative analysis

CPHI Key Highlights

• Market capitalization of $2.07M indicates a small-cap company with potential for high growth but also higher risk.
• Negative profit margin of -76.9% reflects significant challenges in achieving profitability.
• Negative gross margin of -3.2% highlights inefficiencies in production and cost management.
• Beta of 1.09 suggests the stock's volatility is similar to the overall market.
• No dividend yield indicates that the company is not currently returning profits to shareholders, potentially prioritizing reinvestment for growth.

Who Are CPHI's Competitors?

CPHI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CPHI's Key Strengths?

• Established presence in the Chinese pharmaceutical market.
• Diverse product portfolio of generic and branded pharmaceuticals.
• Extensive distribution network and sales force.
• Local manufacturing capabilities.

What Are CPHI's Weaknesses?

• Negative gross and profit margins.
• Small market capitalization.
• Limited financial resources.
• Dependence on the Chinese market.

What Could Drive CPHI Stock Higher?

• Expansion of product portfolio with new generic drug approvals.
• Increased market penetration in existing geographic regions.
• Government policies supporting generic drug usage in China.
• Potential strategic partnerships or acquisitions to expand capabilities.

What Are the Key Risks for CPHI?

• Financial-distress signal — its Altman Z-Score of -1.63 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-19.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from other generic drug manufacturers in China.
• Pricing pressures and regulatory changes affecting the pharmaceutical industry.
• Quality control and compliance issues related to manufacturing processes.
• Economic slowdown in China impacting healthcare spending.
• Negative gross and profit margins impacting financial stability.

What Are the Growth Opportunities for CPHI?

• Expanding Product Portfolio: China Pharma has the opportunity to expand its product portfolio by developing and marketing new generic drugs that address unmet medical needs in China. The Chinese pharmaceutical market is growing, and there is increasing demand for affordable generic medications. By investing in research and development and strategic partnerships, CPHI can introduce new products and increase its market share. This expansion could target therapeutic areas with high growth potential, such as cardiovascular diseases and diabetes. The timeline for this growth opportunity is ongoing, with continuous product development and launches expected.
• Penetrating Deeper into Existing Markets: China Pharma can focus on increasing its market penetration in existing geographic regions and customer segments. By strengthening its relationships with hospitals and private retailers, CPHI can increase its sales volume and market share. This can be achieved through targeted marketing campaigns, improved customer service, and competitive pricing strategies. The company's extensive sales network of approximately 1,000 representatives provides a strong foundation for this growth opportunity. The timeline for this growth opportunity is ongoing, with continuous efforts to expand its reach and influence in the market.
• Improving Operational Efficiency: China Pharma can improve its operational efficiency by streamlining its manufacturing processes, reducing costs, and optimizing its supply chain. This can lead to improved gross margins and profitability. By investing in advanced manufacturing technologies and implementing lean management principles, CPHI can reduce waste and improve productivity. This growth opportunity is crucial for the company to achieve sustainable profitability and compete effectively in the market. The timeline for this growth opportunity is ongoing, with continuous efforts to improve efficiency and reduce costs.
• Leveraging Government Policies: China Pharma can leverage government policies that promote the use of generic drugs and reduce healthcare costs. The Chinese government is actively encouraging the use of generic medications to make healthcare more affordable and accessible to the population. By aligning its product portfolio and marketing strategies with these policies, CPHI can gain a competitive advantage and increase its sales volume. This growth opportunity requires close monitoring of government regulations and proactive adaptation to policy changes. The timeline for this growth opportunity is ongoing, with continuous adjustments to align with government initiatives.
• Strategic Partnerships and Acquisitions: China Pharma can pursue strategic partnerships and acquisitions to expand its product portfolio, access new markets, and enhance its technological capabilities. By collaborating with other pharmaceutical companies and research institutions, CPHI can accelerate its product development efforts and gain access to innovative technologies. Acquisitions can provide access to new markets and customer segments, as well as economies of scale. This growth opportunity requires careful evaluation of potential partners and acquisition targets to ensure strategic alignment and value creation. The timeline for this growth opportunity is ongoing, with continuous exploration of potential partnerships and acquisitions.

What Opportunities Does CPHI Have?

• Expanding product portfolio with new generic drugs.
• Increasing market penetration in existing regions.
• Leveraging government policies promoting generic drug usage.
• Strategic partnerships and acquisitions.

What Threats Does CPHI Face?

• Intense competition from other generic drug manufacturers.
• Pricing pressures and regulatory changes.
• Quality control and compliance risks.
• Economic slowdown in China.

What Are CPHI's Competitive Advantages?

• Established distribution network in China.
• Portfolio of approved generic pharmaceutical products.
• Local manufacturing capabilities.
• Relationships with hospitals and retailers.

What Does CPHI Do?

China Pharma Holdings, Inc., founded in 1993 and headquartered in Haikou, China, develops, manufactures, and markets generic and branded pharmaceutical and biochemical products. The company primarily targets hospitals and private retailers within the People's Republic of China. Its product portfolio includes a variety of formulations such as dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Key products include Cerebroprotein Hydroloysate injection for memory decline, Gastrodin injection for fatigue and concentration issues, and Propylgallate and Ozagrel Sodium for cardiovascular conditions. The company also offers treatments for hypertension (Candesartan), edema (Bumetanide injection), and various infections (Roxithromycin and Cefaclor tablets). Additionally, China Pharma provides products for digestive diseases, such as Hepatocyte growth-promoting factor and Omeparzole, as well as supplements like Noni Enzyme. The company distributes its products through a network of distributors and a direct sales force of approximately 1,000 representatives across 16 sales offices.

What Products and Services Does CPHI Offer?

• Develops generic pharmaceutical products.
• Manufactures pharmaceutical products in various forms, including injectables, tablets, and capsules.
• Markets pharmaceutical products to hospitals and private retailers in China.
• Offers products for treating conditions such as memory decline, fatigue, and cardiovascular diseases.
• Provides medications for infections, hypertension, and edema.
• Distributes products through a network of distributors and sales representatives.
• Offers food supplements and sanitizers.

How Does CPHI Make Money?

• Develops and manufactures generic and branded pharmaceutical products.
• Sells products to hospitals and private retailers in China.
• Utilizes a distribution network and a direct sales force to reach customers.
• Focuses on both prescription and over-the-counter medications.

What Industry Does CPHI Operate In?

China Pharma Holdings operates in the Drug Manufacturers - Specialty & Generic industry, which is characterized by intense competition and pricing pressures. The Chinese pharmaceutical market is experiencing growth driven by an aging population and increasing healthcare spending. However, generic drug manufacturers face challenges related to regulatory compliance, quality control, and pricing regulations. Companies like China Pharma must navigate this complex landscape by focusing on product innovation, cost efficiency, and strategic partnerships to maintain a competitive edge. The industry is also influenced by government policies aimed at promoting generic drug usage and reducing healthcare costs.

Who Are CPHI's Key Customers?

• Hospitals in the People's Republic of China.
• Private retailers and pharmacies in China.
• Patients seeking affordable generic medications.

CPHI (CPHI) Valuation Context

Valued at $2.07M, CPHI is classified as a micro-cap stock. Relative to its peer group, CPHI's quantitative score of 40/100 is below the peer average of 66/100.

ROE -19%Key Financial Metrics

Return on equity for CPHI stands at -19.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 6.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.28 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -125.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

CPHI's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.63 places it in the distress zone, a signal of elevated financial risk.

Net buyingInsider Activity

The most recent 12 insider filings for CPHI break down as 3 sales and 9 purchases. On net that is roughly 17.7M shares acquired (about $3.2M) — insiders putting money in tends to read as conviction.

CPHI Financials

CPHI Latest News

CPHI Analyst Consensus

CPHI MoonshotScore

Common Questions About CPHI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources